Search Results

The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat alcohol- and cocaine-use disorders, among other indications.

CD70 Targeting Antibodies Clinical Trials Has Witness Increase In Recent Years Driven By Breakthrough & Fast Track Designation By USA FDA

Korro Bio, Inc. announced that it has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement that is expected to result in gross proceeds of approximately $70.0 million, before deducting placement agent fees and estimated offering expenses.

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination of its lead program in pediatric progressive myopia due to lack of efficacy.

According to latest study, the global ophthalmic drugs market size was valued at USD 41.65 billion in 2023 and is anticipated to reach around USD 70.07 billion by 2033, growing at a CAGR of 5.34% from 2024 to 2033. North America led the market with the largest revenue share of 40.13% in 2023.